OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Neparidze on the Implications of Early Data for Belantamab Mafodotin Plus Elotuzumab in R/R Myeloma

July 30th 2024

Natalia Neparidze, MD, discusses clinical implications and future of belantamab mafodotin and elotuzumab in heavily pretreated, relapsed/refractory multiple myeloma.

Dr Sen on the Goal to Identify Actionable Biomarkers of Interest in SCLC

July 30th 2024

Triparna Sen, PhD, discusses the importance of identifying actionable or targetable biomarkers for the management of small cell lung cancer.

Dr Peters on the Use of Biomarkers to Inform Treatment Decision-Making in NSCLC

July 30th 2024

Solange Peters, MD, PhD, discusses biomarkers that may inform treatment decision-making prior to immunotherapy use in non–small cell lung cancer.

Dr Das on the ALINA Trial in Early-Stage ALK+ Lung Cancer

July 30th 2024

Millie Das, MD, discusses key trials that have advanced treatment for patients who present with non–small cell lung cancer.

Dr Opat on Sonrotoclax With Zanubrutinib in Relapsed/Refractory CLL and SLL

July 29th 2024

Stephen Opat, MBBS, discusses sonrotoclax plus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr Ravi on the Potential Use of RCB to Inform Neoadjuvant Strategies in High-Risk Prostate Cancer

July 29th 2024

Praful K. Ravi, MB, BChir, MRCP, discusses the use of residual cancer burden to guide intensified neoadjuvant treatment in high-risk prostate cancer.

Dr Dizman on the Impact of CBM588 on the Gut Microbiome in ICI-Treated Patients With RCC

July 29th 2024

Nazli Dizman, MD, discusses the impact of CBM588 on gut microbiome composition in patients with renal cell carcinoma who received immune checkpoint inhibitors in the first line.

Dr Massarelli on Using Selpercatinib and Pralsetinib in Treating Advanced Non-Small Cell Lung Cancer

July 26th 2024

Erminia Massarelli, MD, PhD, MS, discusses selpercatinib and pralsetinib in treating advanced non-small cell lung cancer.

Dr Reckamp on Amivantamab in EGFR Exon 20–Mutated NSCLC

July 26th 2024

Karen L. Reckamp, MD, MS, discusses the role of amivantamab in the treatment of advanced non–small cell lung cancer.

Dr Sands on the Evolving Role of ADCs in SCLC Management

July 25th 2024

Jacob Sands, MD, discusses updates to the role of antibody-drug conjugates in the treatment of patients with small cell lung cancer.

Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC

July 25th 2024

Fred R. Hirsch, MD, PhD, discusses the activity of HER3-directed agents in patients with non–small cell lung cancer harboring NRG1 mutations.

Dr Wirth on the Safety of Selpercatinib in RET Fusion+ Thyroid Cancer

July 25th 2024

Lori Wirth, MD, discusses the safety selpercatinib in adult or pediatric patients with advanced or metastatic RET fusion–positive thyroid cancer.

Dr Bekaii-Saab on the Ongoing Development of Targeted Therapies in GI Malignancies

July 25th 2024

Tanios Bekaii-Saab, MD, FACP, discusses next-generation sequencing and the development of RAS-targeted therapies in gastrointestinal cancers.

Dr Fürstenau on Safety Data From the GAIA/CLL13 Trial in Untreated CLL

July 25th 2024

Moritz Fürstenau, MD, discusses the safety of venetoclax plus obinutuzumab with/without ibrutinib in fit patients with chronic lymphocytic leukemia.

Dr Gong on the Benefits and Limitations of PARP Inhibitor–Based Regimens in mCRPC

July 25th 2024

Jun Gong, MD, discusses the benefits and limitations of PARP inhibitor–based regimens in metastatic castration-resistant prostate cancer.

Dr Facon on the Implications of Isatuximab Plus VRd in Transplant-Ineligible Newly Diagnosed Myeloma

July 25th 2024

Thierry Facon, MD, discusses clinical implications from the phase 3 IMROZ trial

Dr Morgans on the Relationship Between PSA Levels and Radiographic Progression in nmCRPC

July 25th 2024

Alicia Morgans, MD, MPH, discusses key data from the follow-up analysis of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

Dr Posner on the Mechanism of Action of Danivatirsen in HNSCC

July 25th 2024

Marshall Posner, MD, discusses the mechanism of action of danvatirsen in recurrent and/or metastatic head and neck squamous cell carcinoma.

Dr Saliby on the Correlation Between Intermediate End Points and OS in Metastatic RCC

July 25th 2024

Renee Saliby, MD, MSc discusses the relationship between intermediate end points and overall survival in metastatic renal cell carcinoma.

Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes

July 25th 2024

Julia Rotow, MD, discusses the importance of comprehensive biomarker testing for all patients with NSCLC.